Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | C1S | P09871 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15602933 | 0.91 | SCN9A (0.44) | SCN9AHTR3ACYP17A1SCN5A | |
| SCHEMBL3788348 | 0.76 | CYP17A1 (0.41) | CYP17A1LMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL15602963 | 0.76 | CYP17A1 (0.41) | CYP17A1 | |
| SCHEMBL3784414 | 0.74 | HTT (0.35) | HTTHTR3AS1PR1S1PR3LMNA | |
| SCHEMBL3791621 | 0.73 | MEN1 (0.56) | SCN9ACYP17A1SCN5A | |
| SCHEMBL3782281 | 0.72 | CYP19A1 (0.48) | — | |
| SCHEMBL3780809 | 0.71 | SCN9A (0.37) | SCN9ACYP17A1SCN5A | |
| SCHEMBL12315371 | 0.71 | SCN9A (0.49) | SCN9ACYP17A1SCN5AMAPT | |
| Trifluoroacetic Acid SCHEMBL3776095 | 0.69 | CYP17A1 (0.39) | CYP17A1 | |
| SCHEMBL12315273 | 0.69 | CYP17A1 (0.43) | SCN9ACYP17A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| CN-102803250-B | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2014-04-16 | — | — | CN | disclosed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | HTT 4268/4885SCN9A 2049/4885HTR3A 710/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | HTT 4268/4885SCN9A 2049/4885HTR3A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.